NovoCure Limited Ordinary Shares (NVCR) — 分析摘要
NovoCure Limited Ordinary Shares（NVCR）的市值为1.86十亿美元，最近一年的营收同比增长了+8.3%。净利润率为-20.8%。当前市盈率为-10.8倍。
核心要点
- 营收同比变化+8.3%
- 净利润率-20.8%
- 市盈率-10.8倍
与SURGICAL & MEDICAL INSTRUMENTS & APPARATUS板块的其他公司相比，NVCR的营收增长为+8.3%，市盈率为-10.8倍。
NovoCure Limited Ordinary Shares (NVCR)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗，在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -8.3x — 盈利不足以覆盖利息支出
营业利润率为 -27.2% — 经营亏损显著
净利率为 -25.7% — 亏损显著
最新报表显示自由现金流为负。
NovoCure Ltd is an oncology company with a proprietary platform technology in the United States. Its business involves the development, manufacture, and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis, and other products and technologies for the treatment of Glioblastoma, Non-small cell lung cancer, and Pancreatic cancer. Geographically, the company derives the majority of its revenue from the United States and the rest from Germany, Japan, and other markets.
行业
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
员工人数
1,605
总部
ST. HELIER
Exchange
XNAS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析，不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明：本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。